Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography

This study is ongoing, but not recruiting participants.
Hologic, Inc.
Information provided by (Responsible Party):
Elizabeth A. Rafferty, MD, Massachusetts General Hospital Identifier:
First received: April 30, 2010
Last updated: August 16, 2012
Last verified: August 2012

The primary hypothesis to be tested is:

Detection of breast cancer will be increased with tomosynthesis (3D) imaging.

Condition Intervention
Breast Cancer
Device: Tomosynthesis
Device: standard mammography

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • image quality [ Time Frame: concurrent assessment of image quality with up to two year follow up for development of breast cancer ] [ Designated as safety issue: No ]
    image quality with standard mammography vs tomosynthesis

Estimated Enrollment: 600
Study Start Date: November 2007
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
standard mammography
Device: standard mammography
Experimental: Arm 2
Device: Tomosynthesis
The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
Device: standard mammography


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female
  • Any ethnic origin
  • No contraindication for routine bilateral mammography

Exclusion Criteria:

Potential subjects with any of the following will not be enrolled in the study:

  • Any contraindications to mammographic screening, including, but not limited to:
  • Significant existing breast trauma
  • Under the age of 30 at the time of consent
  • Breast Implants
  • Prior Surgeries

    • Unable to understand and execute written informed consent
    • Pregnant
    • Lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01669148

United States, Massachusetts
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Hologic, Inc.
Principal Investigator: Elizabeth A Rafferty, MD Massachusetts General Hospital
  More Information

Responsible Party: Elizabeth A. Rafferty, MD, Director of Breast Imaging, Massachusetts General Hospital Identifier: NCT01669148     History of Changes
Other Study ID Numbers: 2007p-001197 
Study First Received: April 30, 2010
Last Updated: August 16, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on January 18, 2017